Skip to content

Clinical Observation on the Impact of Renal Function by Aspiration and Sclerotherapy of Giant Renal Cysts in Congenital Polycystic Kidney Disease under Internal Medicine Treatment

Clinical Observation on the Impact of Renal Function by Aspiration and Sclerotherapy of Giant Renal Cysts in Congenital Polycystic Kidney Disease under Internal Medicine Treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107723
Enrollment
Unknown
Registered
2025-08-18
Start date
2023-08-03
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital polycystic kidney disease (PKD)

Interventions

Observation group:None
Control group:None

Sponsors

CHIINA-JARAN FRIENDSHIP HOSPITAL
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Polycystic kidney and polycystic liver with large cysts larger than 5cm causing compression symptoms, lumbar and abdominal distension and pain, and huge masses on the epidermis; 2. Polycystic kidney disease and polycystic liver cause difficulty in eating, hiccups and regurgitation that can lead to vomiting; 3. Intermittent microscopic and gross hematuria cannot be relieved; 4. Liver and kidney vesicles grow rapidly and hugely, accompanied by uncontrollable hypertension and heart failure; 5. Cysts accompanied by bleeding or infection.

Exclusion criteria

Exclusion criteria: 1. Polycystic kidney and polycystic liver with large cysts larger than 5cm and causing compression symptoms, such as abdominal distension and pain, and huge masses on the epidermis. 2. Renal pelvis cyst communicating with the ureter; 3. Congenital intrahepatic bile duct cystic ectasia or liver cyst communicating with intrahepatic bile ducts; 4. People who are allergic to polidocanol/polycinyl alcohol and alcohol; 5. Those with severe cardiovascular and cerebrovascular diseases, severe mental disorders, poor compliance, and inability to tolerate treatment; 6. Those who have bleeding tendency and coagulation dysfunction during anticoagulation therapy; 7. Cystic lesions such as hilar blood vessels or renal arteriovenous dilation, pseudoaneurysm, arteriovenous malformations, etc.; 8. Those who do not have a safe puncture path and cannot avoid important blood vessels, bile ducts and important structures.

Design outcomes

Primary

MeasureTime frame
Vesicle size;

Secondary

MeasureTime frame
Renal function;

Countries

China

Contacts

Public ContactZhou Li

China-Japan Friendship Hospital

zhouli_zryy@163.com+86 158 0142 1881

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026